Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 164,012 shares at $5.13 ($841K) on 2022-03-18, disclosed to the SEC on 2022-03-22.
Open-market sale of $841k ROIV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.13 | 82,006 | $421K | 50.0% |
| 2 | $5.13 | 82,006 | $421K | 50.0% |
| Total | $5.13 avg | 164,012 | $841K | 100% |
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |